Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Trial Profile

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2017 Primary endpoint (Restless Leg Syndrome Rating Scale) has been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 23 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top